Persistent URL of this record https://hdl.handle.net/1887/103261
In Collections
This item can be found in the following collections:
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
- All authors
- Schwartz, G.G.; Bessac, L.; Berdan, L.G.; Bhatt, D.L.; Bittner, V.; Diaz, R.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; Jukema, J.W.; Mahaffey, K.W.; Moryusef, A.; Pordy, R.; Roe, M.T.; Rorick, T.; Sasiela, W.J.; Shirodaria, C.; Szarek, M.; Tamby, J.F.; Tricoci, P.; White, H.; Zeiher, A.; Steg, P.G.
- Date
- 2014-11-30
- Journal
- American Heart Journal
- Volume
- 168
- Issue
- 5
- Pages
- 682 - 689